This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Y. L. Articles by Csernus, B. Search for Related Content PubMed PubMed Citation Articles by Wang, Y. L. Articles by Csernus, B.

JMD 2006, Vol. 8, No. 2
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology

Molecular Monitoring of Chronic Myelogenous Leukemia

Identification of the Most Suitable Internal Control Gene for Real-Time Quantification of BCR-ABL Transcripts

Y. Lynn Wang^*, Joong Won Lee^*, Ethel Cesarman^*, David K. Jin and Balazs Csernus^*

From the Department of Pathology and Laboratory Medicine, * and the Division of Hematology, Department of Medicine, Weill Medical College of Cornell University, New York, New York

Monitoring breakpoint cluster region-Abelson kinase (BCR-ABL) levels in patients treated for chronic myelogenous leukemia (CML) has become an integral part of patient management. Real-time reverse transcriptase-polymerase chain reaction is the method of choice for this purpose because of its high analytical sensitivity and reproducibility. Given the variation of RNA quality and quantity in clinical specimens, accurate quantitative assessment of BCR-ABL depends on normalization of the BCR-ABL signal to an appropriate internal reference. However, the controls used by different laboratories vary, and there is no clear consensus on an ideal reference due to limited investigations. In this study, we compared nine commonly used control genes for three criteria: mRNA abundance, levels in CML and non-CML cells, and their degradation kinetics in comparison with BCR-ABL. We found that ß-glucuronidase (GUSB) is the most suitable among the nine genes tested. Although ABL is most widely used, our data suggest that the amount of ABL is different in CML and non-CML cells. Moreover, ABL levels are regulated by cellular stress. These findings have a direct impact on current clinical laboratory practice and patient care because the use of a proper control gene affects the reported levels of BCR-ABL transcripts used for patient management decisions.

This article has been cited by other articles:

				T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 178 - 185. [Abstract] [Full Text] [PDF]

				R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143. [Abstract] [Full Text] [PDF]

				Z. Jobbagy, R. van Atta, K. M. Murphy, J. R. Eshleman, and C. D. Gocke Evaluation of the Cepheid GeneXpert BCR-ABL Assay J. Mol. Diagn., April 1, 2007; 9(2): 220 - 227. [Abstract] [Full Text] [PDF]

				J. W. Lee, Q. Chen, D. M. Knowles, E. Cesarman, and Y. L. Wang {beta}-Glucuronidase Is an Optimal Normalization Control Gene for Molecular Monitoring of Chronic Myelogenous Leukemia J. Mol. Diagn., July 1, 2006; 8(3): 385 - 389. [Abstract] [Full Text] [PDF]